Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Currie

Showing results (201-210 of 231) with videos related to

Pageof 24
Sort By:
Talanta|March 5, 2018
Rapid and robust analytical protocol for E. coli STEC bacteria subspecies differentiation using whole cell MALDI mass spectrometryKevin Mclean, Javier Palarea-Albaladejo, Carol G Currie, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2015
MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP EffluxBoris Tchernychev, Pei Ge, Marco M Kessler, et al.
Plos One|July 30, 2015
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialBrian E Lacy, Ron Schey, Steven J Shiff, et al.
Journal of Medicinal Chemistry|April 5, 2002
Synthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitorE Ann Hallinan, Sofya Tsymbalov, Clifford R Dorn, et al.
European Journal of Pharmacology|September 25, 2010
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transitRobert W Busby, Alexander P Bryant, Wilmin P Bartolini, et al.
Life Sciences|March 24, 2010
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tractAlexander P Bryant, Robert W Busby, Wilmin P Bartolini, et al.
Journal of Gastroenterology and Hepatology|January 11, 2018
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regionsYunsheng Yang, Jingyuan Fang, Xiaozhong Guo, et al.
Science (New York, N.Y.)|October 19, 1973
The Lunar Laser Ranging Experiment: Accurate ranges have given a large improvement in the lunar orbit and new selenophysical informationP L Bender, D G Currie, S K Poultney, et al.
The American Journal of Gastroenterology|September 19, 2012
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safetyWilliam D Chey, Anthony J Lembo, Bernard J Lavins, et al.
The American Journal of Gastroenterology|November 2, 2017
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialPhilip Schoenfeld, Brian E Lacy, William D Chey, et al.
Pageof 24

Showing results (201-210 of 231) with videos related to

Sort By:
Pageof 24
Talanta|March 5, 2018
Rapid and robust analytical protocol for E. coli STEC bacteria subspecies differentiation using whole cell MALDI mass spectrometryKevin Mclean, Javier Palarea-Albaladejo, Carol G Currie, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2015
MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP EffluxBoris Tchernychev, Pei Ge, Marco M Kessler, et al.
Plos One|July 30, 2015
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialBrian E Lacy, Ron Schey, Steven J Shiff, et al.
Journal of Medicinal Chemistry|April 5, 2002
Synthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitorE Ann Hallinan, Sofya Tsymbalov, Clifford R Dorn, et al.
European Journal of Pharmacology|September 25, 2010
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transitRobert W Busby, Alexander P Bryant, Wilmin P Bartolini, et al.
Life Sciences|March 24, 2010
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tractAlexander P Bryant, Robert W Busby, Wilmin P Bartolini, et al.
Journal of Gastroenterology and Hepatology|January 11, 2018
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regionsYunsheng Yang, Jingyuan Fang, Xiaozhong Guo, et al.
Science (New York, N.Y.)|October 19, 1973
The Lunar Laser Ranging Experiment: Accurate ranges have given a large improvement in the lunar orbit and new selenophysical informationP L Bender, D G Currie, S K Poultney, et al.
The American Journal of Gastroenterology|September 19, 2012
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safetyWilliam D Chey, Anthony J Lembo, Bernard J Lavins, et al.
The American Journal of Gastroenterology|November 2, 2017
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialPhilip Schoenfeld, Brian E Lacy, William D Chey, et al.
Pageof 24